This usually happens only in people who had very low vitamin B12 levels before starting B12 supplementation and who are receiving higher-dose treatment, such as injections, rather than daily supplements
That is a rare clinical scenario and it is not the use case being marketed to the public
Well break it down into two distinct scenarios
A gap between robust animal evidence and absent human trial data defines the current state of BPC-157 Supplement research, positioning the compound as investigational rather than clinically validated for tendon repair
What the Science Actually Shows Learn whether retatrutide suppresses appetite, how its triple agonist mechanism works, and what clinical trials reveal
REDEFINE 11: a higher-dose follow-up Novo Nordisk has a higher-dose CagriSema trial (REDEFINE 11) running in parallel, expected to report in the first half of 2027